RxDoctor Payments Data

Barath Krishnamurthy, MD

Interventional Cardiology · Salem, ORNPI 1962434498

Payments from drug & device makers

What this record shows

This record is dominated by education: $4,900 of the $6,726 with a category attached, or 72.8%. Angiodynamics, Inc. accounts for 71.4% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $2,713 and has fallen 86.5% since, to $367 in 2025.

$6,726in general payments, 2019–2025

Across 89 payments — averaging $75.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$5K
  • Novartis$882
  • Pfizer$130
  • Edwards Lifesciences$127
  • Boston Scientific$118
  • AstraZeneca$100
  • plus $569 from 14 others

What the payments were for

  • Food & beverage$1,82627%
  • Education$4,90073%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,726 in reported general payments places this provider in the 60th percentile of 68 interventional cardiology providers in Oregon.

See all interventional cardiology providers in Oregon

Medicare billing

Part B allowed, 2024
$370,912
Medicare patients
755
Services billed
2,732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban618$700,889
EntrestoSacubitril/Valsartan237$236,573
XareltoRivaroxaban134$159,252
Repatha SureclickEvolocumab165$118,056
JardianceEmpagliflozin81$93,163
FarxigaDapagliflozin Propanediol64$66,134
BrilintaTicagrelor55$34,217
Metoprolol Succinate985$13,639
Praluent PenAlirocumab14$12,043
Flecainide Acetate208$7,762
Atorvastatin Calcium730$6,932
Rosuvastatin Calcium382$6,589
BystolicNebivolol Hcl15$5,372
Ezetimibe206$5,016
Carvedilol473$4,430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$130$700,889618 claims
NovartisEntresto, Diovan$882$239,910249 claims
AstraZenecaFarxiga, Brilinta$100$100,350119 claims
Boehringer IngelheimJardiance$40$93,16381 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 68 interventional cardiology providers in Oregon.

Other interventional cardiology in Salem

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →